PTC targets genetic disorders caused by nonsense mutations. Nature , 87—91 Cohen, F. Therapeutic approaches to protein-misfolding diseases. Robert, R. Structural analog of sildenafil identified as a novel corrector of the Fdel-CFTR trafficking defect. Basseville, A. Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter.
Ma, T. High-affinity activators of cystic fibrosis transmembrane conductance regulator CFTR chloride conductance identified by high-throughput screening. Hillebrand, M. Nalepa, G. Drug discovery in the ubiquitin-proteasome system. Grove, D. Cell 20 , — Genin, E. Induction of the adrenoleukodystrophy-related gene ABCD2 by thyromimetics. Steroid Biochem. Kerem, E. Pharmacologic therapy for stop mutations: how much CFTR activity is enough?
The therapeutic potential of targeting ABC transporters to combat multi-drug resistance.
Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Cell Mol. Mlejnek, P. Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels. Ween, M. The role of ABC transporters in ovarian cancer progression and chemoresistance. Fletcher, J. ABC transporters as mediators of drug resistance and contributors to cancer cell biology.
Drug Resist. Beretta, G. Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents. Kannan, P. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Choi, Y. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Center for Drug Evaluation and Research CDER in vitro metabolism- and transporter-mediated drug-drug: interaction studies guidance for industry.
The P-glycoprotein multidrug transporter. Mao, Q. AAPS J. Goldstein, L. Expression of a multidrug resistance gene in human cancers. Natl Cancer Inst. Amiri-Kordestani, L. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.
Robey, R. Anticancer Agents Med. Leonard, G. The role of ABC transporters in clinical practice. Oncologist 8 , — Binkhathlan, Z.
P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Cancer Drug Targets 13 , — Blood 93 , — Witherspoon, S. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG ABC transporters and inhibitors: new targets, new agents. Drugs 3 , — Cancer Lett.
Minderman, H. VX biricodar increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Qadir, M. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Pheophorbide a is a specific probe for ABCG2 function and inhibition. List, A. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
Blood 98 , — Cripe, L. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group Blood , — Libby, E.
Dismounting the MDR horse. Dy, G.
Targeting multidrug resistance in cancer by natural chemosensitizers
Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J. Wei, X. Oncologist 22 , —e43 Lin, J. Oncologist 21 , —e Dai, C. Lapatinib Tykerb, GW reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Mi, Y. Apatinib YND1 reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.
Tiwari, A. Katayama, R. P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. EBioMedicine 3 , 54—66 Mathias, T. New Drugs 33 , — Dohse, M. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab. Kerklaan, B.
go Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. Cancer , — George, A. Wilson, C. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Patch, A. Whole-genome characterization of chemoresistant ovarian cancer.
Huff, L. Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples. Characterization of gene rearrangements leading to activation of MDR Gillet, J. Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.
Marzac, C. ATP binding cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of acute myeloid leukemia patients. Haematologica 96 , — Bartholomae, S. Coexpression of multiple ABC-transporters is strongly associated with treatment response in childhood acute myeloid leukemia. Blood Cancer 63 , — Patel, C. Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity. Raaijmakers, M. Ho, M. Mohelnikova-Duchonova, B. Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues.